IRB00086610                                                                                                                                                                                                   Page 1 of 41 
 
v. 11_ 02.01.19  
   
 
Safety of Intranasal Ketamine for Reducing U ncontrolled 
Cancer Related Pain 
 
Winship EU3238-16 
IND 133570 
Study ID: [REMOVED] 
 
 Principal Investigator  Vinita Singh, MD  
Assistant Professor, Department of Anesthesia  
   
Protocol Version Date : 02/01/2019 
 
 
 
  
 
  
 
 
 
 
 
 
IRB00086610                                                                                                                                                                                                   Page 2 of 41 
 
v. 11_ 02.01.19  
   
TABLE OF CONTENTS  
A. SIGNIFICAN CE‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶....3 
A.1   Background‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...4 
A.2   Pharmacokinetics‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..5 
A.3   Preliminary Data‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...6  
B. INNOVATION‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..7 
Objectives‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶ ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..7 
 C. APPROACH‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶ ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..9 
C.1   Study design and methods‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.9 
C.2   Methods‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.9 
        TABLE of  Assessments‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.11 
         Dose Finding‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.12 
         Pharmacokinetics‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..12 
         Patient Reported Outcomes ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...13 
C.3   Monitoring and Documentation‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.....14 
             C.4   Potential Risks‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶....15 
             C.5   Management of specific side effects‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..16 
             C.6   Benefits‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...17 
             C.7   Participant Selection ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...17 
             C.8   Inclusion Criterion‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..18              C.9   Exclusion Criterion‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.18 
             C.10 Informed Consent Process‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..20 
             C.11 Compensation for time and effort‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...20              C.12 Statistical Analysis ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..20 
             C.13 Data and Safety Monitoring and Reporting‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶....21                           Confidentiality ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶....24 
C.14 Potential Pitfalls‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..24 
 
D. REFERENCES/BIBLIOGRAPHY ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.24 
 APPENDIX I: Assessment scales under in the study  
A. Numerical Pain rating scale ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..29 
B. SERSDA (Side effects Rating Scale for Dissociative Anesthetics)‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.29 
C. ECOG (Eastern Cooperative Oncology Group) Performance Status‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...29 
D. ESAS (Edmonton Symptom Assessment System) Score ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.30 
E. RASS (Richmond Agitation -Sedation Scale) Scale to Assess Sedation ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..31 
F. CAM-ICU ( Confusion Assessment Method for the Intensive Care Unit) scale to assess  
for delirium ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...32 
G. PHQ-9 (Patient Health Questionnaire)‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.33 
H. MADRS (Montgomery -Asberg Depressions Scale) Questionnaire‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.34 
I. PROMIS Questionnaire‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶35 
J. Pain Diary ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.36 
APPENDIX II  
A. Summary sheets from NMS Labs‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.37 
B. Ketamine package insert ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...38 
IRB00086610                                                                                                                                                                                                   Page 3 of 41 
 
v. 11_ 02.01.19  
  C. Ketamine Safety Data Sheet, Hospira ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...39 
D. Cytochrome P450 3A4 and 3A5 Known Drug Interaction Chart‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶.40 
 
A. SIGNIFICANCE:  
 There are about 11.9 million Americans affected with cancer; of these, 53% of patients with cancer 
experience pain at all stages of cancer. The number rises to 58 to 69% in those with advanced cancer 1.  
Depression often co -exists with cancer pain. Patient s with cancer pain often require high dosages of 
opioids that make them too sedated to effectively participate in day- to-day activities and have a good 
quality of life. Occasionally, even after high dose opioids their pain remains uncontrolled in the setti ng of 
opioid tolerance or opioid unresponsive pain. An epidemiological study revealed that 10 to 15% of these 
patients fail to achieve acceptable pain relief with opiates alone or in combination with conventional adjuvant analgesics 
5-7. Opioid medications  are associated with numerous side effects such as: 1) Most 
commonly- constipation, sedation, nausea and vomiting, respiratory depression, urinary retention, and 
pruritus. 8-11, 2) Tolerance, causes loss of treatment effectiveness forcing the increase of d osage, which 
simultaneously entails a greater risk for ADRs 12 , 3) Increased pain sensitivity, also known as 
hyperalgesia, can appear during opioid treatment, despite increasing dosage of opioids or steady state of disease
13, 4) Immunosuppression leading to significant infections has been demonstrated for opioids in 
experimental studies 14, 5) Hypogonadism caused by the central suppression of hypothalamic secretion of 
gonadotropin releasing hormone 15 6) Hyperglycemia by decreasing the insulin secretion through the 
sympathetic nervous system 16  and 7) ‚ÄúStress cardiomyopathy‚Äù, also known as Takotsubo 
cardiomyopathy (transient left ventricular dysfunction, usually triggered by intense emotional or physical stress), could appear whe n withdrawing opioid 
17.  
 
The need to identify and evaluate new evidence- based interventions, including pharmacologic agents, to 
address cancer pain is a priority for the NIH as well as global public health agencies. The NIH Pain 
Consortium was established in 1996 to enhance pain research and promote collaboration among investigators across the NIH. Currently, the research interests of 21 NIH Institutes, Centers, and Offices are represented in the Consortium. In 2011, the Institute of Medicine (IOM) releas ed its landmark report,  
Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, 
which outlines the state of the science of pain prevention, care, training, and research, and provides a guide 
intended to transform pain care in the United States. NIH, in response, set forth a program of research 
funding for all conditions, including cancer, for which pain is a prominent component. The Cochrane Pain, Palliative and Supportive Care Group has urged the generation of evi dence for effective, well- tolerated 
IRB00086610                                                                                                                                                                                                   Page 4 of 41 
 
v. 11_ 02.01.19  
  pain interventions. Despite these efforts, the understanding and treatment of cancer pain remains 
inadequate.  
 
A1. Background: 
 In the search for improved therapies for chronic cancer pain, medications with novel mechanisms of action 
have been sought. One such promising pharmacologic approach is ketamine.  
 Ketamine is an FDA approved anesthetic with amnesic, analgesic, dissociativ e, and sedative properties. It 
is unique among anesthetic agents in that it does not depress cardiovascular and respiratory systems.  
Ketamine is a noncompetitive, antagonist of N-methyl-D-aspartate (NMDA) receptors that blocks the 
NMDA channel in the open state by binding to the phencyclidine (PCP) site located within the lumen of 
the channel. Antagonism of NMDA receptors produces antinociception of persistent or neuropathic pain in animal models and analgesia in pain states in humans. The NMDA receptor is  believed to play a role in 
the development of opioid tolerance and ketamine has been shown in a rat model to prevent fentanyl -
induced hyperalgesia and subsequent acute morphine tolerance 
18. Ketamine also interacts at a number of 
other receptor sites to b lock pain. Some of these sites include voltage -sensitive calcium channels, 
depression of sodium channels, modulation of cholinergic neurotransmission, and inhibition of uptake of 
serotonin and norepinephrine. Ketamine also interacts with kappa and mu opioi d receptors; however, in 
humans, naloxone, an opioid antagonist, does not antagonize the analgesic effects of ketamine. Safety and efficacy of ketamine as an anesthetic and analgesic agent is well documented 
2-4. Ketamine is not labeled 
by the FDA as an analgesic agent. Low (subanesthestic) doses of ketamine have minimal adverse impact 
upon cardiovascular or respiratory function but produce analgesia and modulate central sensitization, 
hyperalgesia, and opioid tolerance. Cancer pain, especially in end stages, can be very complicated and is mediated by a variety of pathways: visceral, nociceptive, neuropathic and central. If ketamine can be 
utilized for pain in end stage cancer patients, this could provide them with superior analgesia and better 
quality of li fe, without the risk of significant respiratory depression associated with opioid medications.  
 
One of the challenges that we face with ketamine is the route of administration. The most common route 
is intravascular or intramuscular. Although it has been given orally and rectally, the bioavailability of 
ketamine when given via these routes is limited to 20 -30%. Intranasal (NAS) administration represents a 
promising route because of:   
1) Potential method of ketamine maintenance therapy as an outpatient;   
2) Ease of access as a needle- free, patient -friendly route of administration;  
3) Higher bioavailability compared to oral route due to absence of hepatic first    
                          pass effect; and   
IRB00086610                                                                                                                                                                                                   Page 5 of 41 
 
v. 11_ 02.01.19  
  4) Large surface area, uniform temperature, high permeabi lity and extensive  
vascularity of the nasal mucosa facilitate rapid systemic absorption of intranasal 
administered drugs [19]. 
 
Intranasal ketamine has been shown to be effective in controlling breakthrough pain in a double blind 
randomized control trial (DBRCT) performed by Carr in 2003, as well as help with depression in a DBRCT by Lapidus in 2014 
20,21. Both studies were NIH fun ded. The Carr study was a DBRCT in 20 patients with 
breakthrough pain and noted pain relief within 10 min, lasting up to 60 minutes with 10- 50 mg of intranasal 
ketamine (2.65 point average decrease on NPRS scale). The pain scores were only recorded until 6 0 
minutes after the drug administration and the patients were allowed to determine the dose themselves, without precise description for this in the study. Lapidus study was performed in 20 patients with major depression and noted significant improvement in depressive symptoms (7.6 point average decrease on 
MADRS scale) in 44% of patients at 24hrs with 50mg of intranasal ketamine. There are limited data regarding the use of ketamine as an adjuvant to opioids for the management of cancer pain
22. We seek to 
obtain preliminary data on safety, feasibility, and utility of this novel technique for the treatment of uncontrolled cancer pain. Ketamine is a scheduled III medication. Intranasal ketamine can be ordered by a physician from a compounding pharmacy.   
  
A2.  Pharmacokinetics :  
Ketamine has a rapid onset and relatively short duration when administered as a single intravenous dose.  
Onset of action for intravenous dose is 30 seconds; distribution half -life 10 minutes; elimination half -life 
2-3 hours. Oral b ioavailability is poor (20 -25%) possibly due to the hepatic first pass effect/GI tract effect. 
Ketamine undergoes rapid demethylation to norketamine via cytochrome P450 (CYP) conversion, with 
CYP3A4 being the principle pathway, with minor and clinically insignificant contributions from CYP2B6 and CYP2C9. 
50 Bioavailability of intranasal ketamine was found to be 50% in children aged 2- 9 year old 
in a study done by Malinkovsky et  al. in 1996 2.  However this study was done in children and the subjects 
did not serve as their own controls. In a study by Yanagihara et  al. in 2002 the bioavailability of intranasal 
ketamine was found to be 45%. In this study the subjects served as their own controls, however, the number of subjects was limited to 3. The time for  maximum concentration after intranasal  ketamine administration 
was found to be 22.5(+ - 9.6) min for ketamine and 120(+ - 52) min for its metabolite norketamine. The T
1/2 
Œ≤ (elimination half -life) of IV ketamine is reported to be 126.8(+ -47.4) min by Yanagi hara et al 23.  
Elimination half -life of intranasal ketamine has not been reported. Ketamine has high lipid solubility and 
crosses the blood -brain barrier quickly, and exhibits high hepatic clearance and a large volume of 
distribution.  It undergoes extensive hepatic metabolism by the cytochrome P -450 system to form the 
IRB00086610                                                                                                                                                                                                   Page 6 of 41 
 
v. 11_ 02.01.19  
  active metabolite, norketamine.   Norketamine is one -third to one -fifth as potent as Ketamine.  
Norketamine is eventually conjugated to form more inactive metabolites that are excreted by th e kidneys.     
 
A3. Preliminary Data: 
To date, we have collected data on two cases of cancer patients to whom ketamine was delivered 
palliatively for pain unresponsive to usual interventions:  
 
Case 1.  A 38 year old female with squamous cell cancer of the tongue with bone and lung metastases and 
cord compression had back/spinal pain rated as 9- 10/10 on NPRS. Increasing opioid medications 
paradoxically increased her pain, representing opioid- induced hyperalgesia. She had failed 
antineuropathic medications and was admitted for the neurological s ymptoms secondary to cord 
compression. Intravenous ketamine was initiated. On day 1, her pain score reduced to 8- 10/10 and on day 
2 went to 4- 7/10. On day 2 she was switched to intranasal ketamine (10 mg BID), so it could be continued 
after discharge at ho me. On day 3, her pain score decreased to 2- 6/10, and she was slowly titrated to 20 
mg BID. Her pain score reduced further to 0- 7/10 on day 5, however, she developed complications from 
her primary disease and could not be discharged. Throughout her stay sh e received intranasal ketamine 
without reported side effects except for one episode of bloody mucus discharge after blowing her nose 
when she first started.   
 
Case 2. A 74 year old female with multiple myeloma in remission had developed severe peripheral 
neuropathy and chronic diarrhea secondary to adverse effects of multiple myeloma therapy. She had multiple osseous lesions in pelvis and right femur s/p radiation thera py. However, she complained of pain 
in her right sacrum radiating to the front of her groin. Although she had full motor strength, she remained bedridden secondary to pain and peripheral neuropathy causing imbalance. She had failed multiple medications inc luding opioids and interventions such as steroid injections. She remained on morphine 
extended release, and was started on ketamine IV while in the hospital and appeared to respond, although she still reported high pain scores. When ketamine was stopped, she went into a pain crisis again. The decision was thus made to continue NAS ketamine 10mg BID at home. She tolerated this dose and did not report any side effects. She maintained good pain control and required no further pain related hospital 
visits.  Bas ed on these limited preliminary data, a formal clinical pharmacology and efficacy study is 
indicated to evaluate intranasal ketamine in cancer -related pain.  
   
  
IRB00086610                                                                                                                                                                                                   Page 7 of 41 
 
v. 11_ 02.01.19  
  B. INNOVATION:  
Although ketamine has been used as an adjunct to opioid medication for pain, the re is no data on intranasal 
ketamine for cancer -related pain. If studied extensively, this could potentially provide physicians with a 
simple option and unique adjunct to treat pain. Ketamine could also modulate central  sensitization and 
hyperalgesia which are some of the mechanisms involved in development of chronic pain. This could 
potentially help decrease the severity of pain in general. Depression often coexists with cancer, and 
intranasal ketamine has the potential to improve depress ive symptoms when used chronically.  
   
Intravenous ketamine is used by pain physicians to control pain not responding to opioid medications in 
the hospital setting. However, it is not continued as an outpatient therapy as absorption of oral ketamine is limited to 25%. Intranasal ketamine, if feasible, will provide clinicians with an option to continue 
ketamine chronically. There is also lack of long term studies regarding use of ketamine for pain. Future long term studies with intranasal ketamine for pain c ontrol can be designed based on data obtained from 
the current proposed study.  
 
 The route of administration can be limited in terminally ill patients as many suffer from nausea and 
vomiting (limiting the oral route) and have dehydration making it difficult to find veins for intravenous route. A study, focusing on the effects of chemotherapy on Chemotherapy Induced Nausea Vomiting 
(CINV), and the effect of CINV on daily life found that 36% of all patients reported emesis and 60% 
reported nausea. Intranasal  route is underutilized for medication administration, especially pain 
medications in cancer patients. If successful, this study will open new horizons of medication delivery and pain control in this population.  
  
Objectives    
Overall Goal: To determine the safety, feasibility, and utility of intranasal (NAS) ketamine in 
persistent uncontrolled cancer related pain.  
Specific Aims:  
Primary Outcomes  
1. To conduct a clinical trial of NAS ketamine in a sample of patients with cancer r elated pain.  
1a. To measure pharmacokinetics of NAS ketamine through analysis of ketamine and its 
metabolite norketamine to determine pharmacokinetic variables including peak concentration 
after each dose and route (C
max), time to peak concentration (t max), total area under -the-
concentration -time curve (AUC 0-t), half-life (t1/2), and clearance (Cl) . 
IRB00086610                                                                                                                                                                                                   Page 8 of 41 
 
v. 11_ 02.01.19  
  2. To evaluate (pharmacodynamic) effects of NAS ketamine on Patient Reported Outcomes 
(PROs), such as pain scores, side effects, depression, health -related quality of life, and 
functional status.   
2a. To assess PROs as measured by the Numerical Pain Rating Score (NPRS), Side Effect Rating Scale for Dissociative Anesthetics (SERSDA), Montgomery Asberg Depression Rating  
Scale (MADRS), and Edmonton Symptom Assessment (ESAS), Eastern Cooperative Oncology Group (ECOG) and Patient -Reported Outcomes Measurement Information System 
(PROMIS) scales.   
Secondary Outcomes  
3. To determine opioid sparing effect of NAS ketamine.    
3a. To document use of rescue medications prior to and during the study 3b. To evaluate total opioid consumption prior to and during the study.  
 
If intranasal ketamine can be utilized for pain control in cancer patients, this could provide them with 
superior analgesia and better quality of life, without the risk of significant respiratory depression associated 
with opioid medications. We seek to obtain preliminary data via a clinical trial addressing safety, 
feasibility, and utility of this novel technique for the treatment of persistent uncontrolled cancer pain. 
These findings would be an important initial step towards testing the effectiveness of intranasal ketamine 
as a non-opioid medication for cancer pain used as potential maintenance outpatient therapy. These initial 
findings would be applied to a subsequent trial to determine the effectiveness and associated toxicities of 
ketamine in a larger sample of cancer patients, and address the compelling need to identify new, successful 
management therapies for cancer pain.   
 
     
 
 
IRB00086610                                                                                                                                                                                                   Page 9 of 41 
v. 11_ 02.01.19 
 

&$3352$&+ 

&6WXG\GHVLJQDQGPHWKRGV 

&0HWKRGV 
7KLVLVDSURVSHFWLYHFOLQLFDOWULDOWRLQYHVWLJDWHWKHXVHRI LQWUDQDVDONHWDPLQHLQSDWLHQWVZLWK
XQFRQWUROOHGSDLQUHODWHGWRFDQFHURUFDQFHUWUHDWPHQW7KHW ULDOZLOOEHFRQGXFWHGLQWKH3KDVH8QLW
RIWKH:LQVKLS&DQFHU,QVWLWXWH:&, 
,QWUDQDVDONHWDPLQHZLOOEHSUHSDUHGIURPDPJP/YLDOWRE HGHOLYHUHGQDVDOO\ZLWKDQDVDODWRPL]HU
:HZLOOGHOLYHUPOWRSURYLGHPJRIDWRPL]HGNHWDPLQH$ OWHUQDWLQJQDUHVZLOOEHXVHGWRGHOLYHU
PODWDWLPHXQWLOWKHIXOOGRVHLVGHOLYHUHG,QWKHLQWUD QDVDONHWDPLQHVWXG\IRUEUHDNWKURXJKSDLQE\
&DUUHWDOWRPJRILQWUDQDVDONHWDPLQHZDVJLYHQUHJDU GOHVVRIWKHSDWLHQW¬∂VZHLJKW,9NHWDPLQH
DQDOJHVLFGRVHVDUH!QJPO/DSLGXVHWDOIRXQGWKHPHDQNHWDPLQHSODVPDFRQFHQWUDWLRQW REH
QJP/DWPLQDQGQJP/DWPLQZKHQPJRILQWUDQDVDO NHWDPLQHZDVJLYHQRYHUPLQ,9
ELRDYDLODELOLW\LVZLWKRUDOELRDYDLODELOLW\RI,QWUDQDVDOELRDYDLODELOLW\LVHVWLPDWHGWREH
IURPSULRUVWXGLHVDQG6WXGLHVIURP.\OH&KULVWHQVHQHWDOKDYHVKRZQVDIHW\ZLWK

IRB00086610                                                                                                                                                                                                   Page 10 of 41 
 
v. 11_ 02.01.19  
  intranasal doses of ketamine at 10 mg, 30 mg and 50 mg 28. Therefore, for study purposes 10mg, 30 mg and 
50mg of intranasal ketamine will be administered.  Each visit will be two to seven days apart to avoid any 
accumulation of study doses.  Subjects will be recruited at the supportive oncology clinic, oncology clinics, 
the pain clinic and Acute Pain Service at Emory. Subjects may be identified and contacted via telephone 
with information about the study prior to their next clinic appointment in order to allow time for them to 
consider the study.  After informed consent has been obtained, study eligibility will be confirmed (see Table 
of Assessments) . An appointment will be made for the Phase I Unit at Winship. A family member/friend 
must transp ort the patient home following drug administration, as driving for 24 hours post drug 
administration is discouraged. Written informed consent will be obtained prior to performance of study 
procedures, either while recruiting prior to study visit one  or during the first study visit, prior to beginning 
the study. Subjects must meet all study eligibility criteria  on Visit 1 prior to study treatment. Patients will 
be asked to return to the Phase 1 Unit for a total of 5 study visits.  All study visits  to the clin ic will take 
place within six weeks  or less. A telephone call  visit will occur 14 days after the last dose of medication 
administered to follow any ongoing adverse event s that occurred during the study period. If there are no 
ongoing adverse events at the end of visit five, the subject‚Äôs participation will end at that time. Subjects 
may be reconsented if withdrawn early, at the discretion of the investigator, provided all eligibility requirements are met.   
 
 
 
  
 
 
 
 
    
 
IRB00086610                                                                                                                                                                                                   Page 11 of 41 
 
v. 11_ 02.01.19  
   
  Table of Assessments  
Assessments  Screening   Visit One  Visit Two  Visit Three  Visit Four  Visit Five  Telephone Call  
Review of 
Inclusion/Exclusion  X       
Informed Consent  X       
Med Hx/Demographics  X       
Hemoglobin (if none within 
3 months of Visit One)   X      
Urine pregnancy test -within 
one week of planned Visit 
(women of child bearing 
potential)   X X X X X  
PHQ9 Depression Screening  X X1      
Completion of PROMIS 
Questionnaire   X    X  
ECOG score   X X X X X  
ESAS   X X X X X  
MADRS2,3  X X X X X  
Height   X      
Weight   X X X X X  
IV access   X X4 X X   
Study Medication 
Administration   X X X X   
Vital Signs(HR5, BP, RR, 
Pulse Oximetry6)  X7 X7 X7 X7 X8  
Blood Samples (PK)   X9 X9,10 X9,10 X9,10 X10  
Hepatic Function test   X    X  
Urinalysis   X    X  
Pain Scores (NPRS)   X7 X7 X7 X7 X8  
RASS scale   X11 X11 X11 X11 X8  
CAM ICU Scale for RASS 
score between +4 to -3  X X X X X  
SERSDA scale   X11 X11 X11 X11 X8  
Olfactory assessment - pre 
and post drug   X X X X   
Adverse Events   X X X X X X12 
Rescue medication use 
details   X X X X X  
Pain Diary13  X X X X X  
Opioid Pill Count   X X X X X  
1If not previously recorded during screening visit  or within 3 months of planned visit one  and no history of depression 
2If screened positive for depression, questionnaire to be administered before medication given  
3Questionnaire to be repeated between 180 and 240 minutes after medication given  
4Two IV‚Äôs needed Visit two: one for study medication, one for blood draw  
5 Monitoring will occur continuously for a minimum of 30 minutes post drug administration  
6Pulse oximetry monitoring will occur continuously for a minimum of 30 minutes post drug administr ation  
7To be recorded at baseline, 5 , 10, 15, 30 (+/- 5), 45(+/- 5), 60 (+/- 5), 120(+/ - 15), 180(+/ - 15) and  240(+/ - 15) minutes  
after medication administration  
8On arrival for study visit  
IRB00086610                                                                                                                                                                                                   Page 12 of 41 
 
v. 11_ 02.01.19  
  9Samples will be obtained at 2, 30(+/ -5), 60 (+/-5) and 240(+/- 15) min after medication administration on visits 1 
through 4.  
10Baseline samples will be drawn on visits 2 to 5 
11Assess at baseline, 30(+/ -5), 60(+/ -5), and 240 (+/- 15) minutes after medication administration  
12  Ongoing a dverse events will be followed by a telephone call 14 days after the last day of study medication 
administration, plus or minus one day. 
13Patient to record data throughout study enrollment, collected at final visit  
 
Dose Finding. Escalating dosages of intranasal  ketamine will be given during the study in order 
to find optimal analgesic dose without significant side effects. On the first study visit, after 
obtaining written informed consent, 10mg of intranasal ketamine will be given to make sure that 
the study pat ients are able to tolerate a small dose of NAS ketamine. On the second visit, 10 mg 
of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients 
serving as their own controls. On the third and fourth visit, higher doses of ketamine, 30 mg and 
50 mg respectively, will be given , if the patients did not have severe adverse events with the 
smaller dosage . Licensed study personnel delegated to do so, will administer ketamine. The 
intranasal ketamine will be administered as follow s: 1) Ensure mucosal atomization device 
(MAD) is primed and the appropriate dose loaded into the syringe. 2) Have patient sit in chair and 
clear sinuses using a tissue if needed. 3) Tilt the patient‚Äôs head back. 4) Insert MAD into nostril 
and aim directly posterior, level with the floor of the nare, and slightly lateral. 5) Administer 
0.1mL (10mg) . 6) Have patient keep his head tilted back for 5 minutes, if tolerable, to ensure that 
the medication does not run out of nares. Make a note if medication is visibly noted to run out of 
nares or if patient reports feeling of medication trickling down his throat. 7) If more than 0.1mL  
(10mg) needs to be delivered, repeat steps 3 -5 in the contralateral nare, alternating until the full 
dose is delivered. Ensure 30 seconds have passed before re -administration into the same nare.  
Patients may continue to take their usual pain medication as needed. Since most of the oral immediate release opioid medications peak between 30 to 90 minutes, ketamine will be given at 
least 120 minutes after the last dose of immediate release opioid medication so the reduction in 
pain score is not confounded with the results of immediate release opioid medications. Pain scores 
will be recorded on NPRS prior to and at 5, 10, 15, 30, 45, 60, 120, and 180 and 240 minutes after 
administration of test medication. NPRS is the most responsive tool to document pain intensity when compared to Visual Analogue Scale (VAS) and Visual Rating Scale (VRS) for measuring 
pain,
 29 showing higher compliance rates, better responsiveness, ease of use, and good applicability 
relative to VAS/VRS30. In general, improvements of pain severity</=1.5 points on NPRS could 
be seen as clinically irrelevant 31-34.  Above that value, the cutoff point for ‚Äúclinical relev ance‚Äù 
depends on patients‚Äô baseline pain severity, and ranges from 2.4 to 5.3 33-35. Higher baseline scores 
require larger raw changes to represent clinically important differences 36.  
IRB00086610                                                                                                                                                                                                   Page 13 of 41 
 
v. 11_ 02.01.19  
  Concomitant Opioid medications : As the study subjects wi ll have uncontrolled pain it is likely 
that they might be on opioid medications during the study. Georgia prescription monitoring 
database will be searched by the investigators and an opioid pill count will be done at each visit to 
monitor opioid intake during the study.   
Pharmacokinetics. Blood samples will be drawn at 2, 30, 60 and 240 minutes. Baseline blood 
samples will be drawn on visits 2 through 5. The specimen requirements for lab testing are 3 ml 
serum or plasma in EDTA containing vacuum tubes. We will draw 6 ml of blood per sample to 
allow for adequate serum/plasma sample. The total blood drawn during one visit would be 24 to 30 mL. Samples will be promptly centrifuged and serum or plasma will be separated into a plastic cryovial and frozen. The plastic containers will be preservative free. All samples will be sent within 3 months to National Medical Services. The samples are valid for 7 months at -20¬∞C, 30 days when 
refrigerated or stored at room temperature. Samples will be destroyed immediately after analysis. 
A gas chromatography with mass spectrometry (GC/MS) analysis of the samples will be done for 
concentrations of ketamine and its metabolite, norketamine. Plasma concentration -time curves for 
ketamine and norketamine will be generated for each subject and compared within subjec ts for the 
variables of route and dose, with IV administration serving as the basis for comparison. 
Additional Labs: Liver function test (LFT) and urinalysis (UA) will be done on visits 1 and 5.  
 
Patient Reported Outcomes. Patients will maintain a pain dia ry(Appendix I-J) for the entire 
study period up until the 5th and final study visit and record how often they took their usual 
breakthrough medication during the trial.  
At home, patients will log pain scores 3 times a day. 10 item PROMIS questionnaire will be filled 
out at first (baseline ) and fifth (final) study visit to assess global health.  Participants will fill out a 
PHQ-9 scale during the screening visit or the first study visit. PHQ-9 scale ranges from 0 to 27 and 
can be used for screening of depression. Patients who are on antidepressants or score more than 4 
on PHQ-9 scale will be assessed for depression during the study. Depression will be assessed on 
the MADRS on each visit . (See appendix 1 F)  This is a 10 item questionnaire designed to be 
particularly sensitive to treatment effects37. Higher MADRS score indicates more severe 
depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 . Participants 
who screen positive for depression and are not on any treatment for depression, will be offered a 
psychiatry consult as a part of their routine healthcare, if interested. Performance status will be 
assessed on ECOG grading at baseline and  throughout the study, which ranges from 0 to 5, where 
0 is fully active and 5 is dead. ESAS will be used to assess 9 common symptoms (pain, t iredness, 
IRB00086610                                                                                                                                                                                                   Page 14 of 41 
 
v. 11_ 02.01.19  
  nausea, depression, anxiety, drowsiness, appetite, well -being, and shortness of breath) experienced 
by cancer patients. Each symptom is rated from 0 to 10 on a numerical scale; with 0 meaning that 
the symptom is absent and 10 that it is the worst possible severity. Patient‚Äôs study participation will 
end with the 5th and final study visit. Patients will be followed up in the pain or supportive oncology 
clinic for their routine  care for pain management. They will be followed up more frequently if 
needed. Patients who benefit from intranasal ketamine would be offered this medication as an outpatient. The dosage and regimen will be decided on a case by case basis by the treating physician.   
  
C.3 Monitoring and Documentation: (See appendix 1 for all scales)   
 
The following assessments will be documented in patient research study record:  
1. Height and weight at the first study visit  
2. Pain intensity on NPRS prior to and at 5, 10, 15, 30, 45, 60, 120, 180 and 240 minutes 
after medication is given  
3. Vital signs including heart rate, blood pressure, respiratory rate and pulse oximetry at 
baseline, and 5, 10, 15, 30, 45, 60, 120, 180 and 240 minutes .  Vital signs and pulse 
oximetry will be monitored continuously for a minimum of 30 minutes post drug 
administration. More frequent vital signs if they are unstable  
4. ECOG and ESAS score at baseline on each visit  
5. Sedation level on RASS scale prior to and at 30, 60 and 240 minutes after medication is 
given  
6. If RASS score is between +4 to -3 then sedation/ delirium assessment on CAM scale will 
be done prior to and at 30, 60 and 240 minutes after medication is given   
7. Side effects on SER SDA scale prior to and at 30, 60 and 240 minutes after medication is 
given  
8. An olfactory assessment will be performed pre and post study drug administration to 
determine if the study medication has impacted the sense of smell. 
9. Rescue medication taken; if taken, was it taken at the usual interval or longer  
10. Patient response to intervention if anything besides change in NPRS is reported  
11. Patient and family education regarding maintaining pain diary and reviewing discharge 
instructions, including when to call study coordinator or report to emergency department  
12. PROMIS functional scale on the first and last day of the study  
13. Any change in health status during the duration of study  
14. Opioid medication pill count at the beginning of each visit 
15. Only for visits 1, 3, and 4: If the patient reports  symptoms of a significant upper 
respiratory tract infection (e.g. rhinorrhea, congestion), the study visit will be canceled 
and re-scheduled at a later date.  
IRB00086610                                                                                                                                                                                                   Page 15 of 41 
 
v. 11_ 02.01.19  
  16. If changes in sense of smell are noted, a study investigator will be notified, and additional 
olfactory assessments will be performed, with the frequency and amount of assessments 
at the discretion of the investigator. 
17. The frequency of the assessments may be increased at the discretion of the investigator.  
  
The study nurse will notify the attending physician if any of the following occur:  
1. Baseline HR >100 or BP>160/100 or pain score  </=3 on NPRS  who will make the 
decision of whether or not to proceed with the study visit or cancel based on the 
inclusion/exclusion criterion  
2. After the study medication is given, vital signs change more than 20% from baseline; 
HR<50 or >110, SBP<90 or >180, DBP<30 or >100, RR<8 or >24 or SaO2<90; Any side effects or unexpected results  
3. Sedation on RASS scale between -1 and -5 a t any time  
4. Positive for delirium on CAM scale at any time  
5. Presence of any possible side effects from the study drug administration  
 
Patients will be deemed eligible for discharge after the 240 minute assessment if they meet the 
following: 
             
‚Ä¢ Vital signs are within 10% of baseline values 
‚Ä¢ RASS score is between +1 and -1 
‚Ä¢    Side effects as noted on the SERSDA scale are valued as 2 or less, or no more than 1 
point greater than their baseline value. Investigator must be notified if val ue is greater 
than 2. 
 
Should the patient not meet these criteria at the end of the 240 minute as sessments, the study 
nurse will contact the research physician for further evaluation and assessment.  
 
C.4 Potential Risks   
 
Adverse effects are dose related. No serious side effects have been reported with intranasal ketamine 
doses of up to 50 mg.   
 
Common side effects of ketamine:  Include sedation, somnolence, sensory illusions, dissociative feelings, 
blurred vision, anorexia, abdominal pain 38, 39, feeling of insobriety 40, 41, and dream disturbances 42. Dose-
dependent side effects include hallucinations, agitation, nightmares, di zziness, and nausea 43. At higher 
doses, side effects may include delirium, impaired motor function, amnesia, anxiety, panic attacks, mania, 
insomnia, and elevated blood pressur e 43. Rarely, hepatic failure43 has been reported in participants with 
IRB00086610                                                                                                                                                                                                   Page 16 of 41 
 
v. 11_ 02.01.19  
  underlying liver disease pr ior to ketamine administration. Additionally, chronic administration of 
ketamine has been associated with ulcerative or hemorrhagic cystitis, which usually resolves with 
cessation of ketamine administration  43. However this was reported in ketamine abusers and dosage being 
used for this study are very low. Additionally, a LFT and UA will be done the day of or up to 24 hours 
before both  visits 1 and 5 to monitor for rare side effects . If obtained as standard of care within this ti me 
frame, these will not need to be repeated  for the study. Benzodiazepines  and neuroleptics have been used 
to successfully minimize psychotomimetic effects, such as psychosis or delirium, when ketamine is used 
for the treatment of pain 44, 45.  
  
C.5 Management of specific side effects  
 
Side effects unique to intranasal route: Include transient change in taste, rhinorrhea and nasal passage 
irritation. If the patient reports that these changes to be persistent beyond the date of administration of 
study drug and are moderate to severe in intensity, then a formal ENT consult will be sought.  
Cardiovascular effects: Potential effects include: increases in heart rate, systemic arterial pressure, 
systemic vascular resistance, pulmonary artery pressure, and pulmonary vascular resistance.  In the 
absence of autonomic control, ketamine has direct myocardial depressant effect, usually overridden by 
central response.  If >20% variation from baseline is noted in  heart rate or blood pressure, study MD will 
be notified. Risk assessment will be done by the MD and appropriate medications will be given as 
deemed necessary. Patient will be admitted to inpatient medical oncology service for 23 hours observation if at the end of study visit a >20% variation persists des pite treatment; HR >120; 
hypertensive urgency/emergence occurs. Hypertensive urgency is defined at SBP>180 or DBP>110. In 
hypertensive emergency signs or symptoms of end organ damage are noted such as blurry vision, 
headache, and chest pain.  
Central nervo us system effects: Include- tremors, increased intracranial pressure, floating sensation, 
hallucinations (auditory and visual), delirium, vivid dreams or illusions, confusion, restlessness, disorientation, dysphoria, dizziness, and sedation.  After discont inuation of ketamine, recurrent illusions 
(flashbacks) can occur.  Ketamine can lower the seizure threshold, especially in patients on aminophylline. 
Benzodiazepines such as midazolam 0.5 mg to 5 mg IV or lorazepam 0.5 mg to 5 mg IV or diazepam 0.5 
mg to 10 mg IV or oral, etc. may be given to mitigate CNS side effects at the discretion of the study MD. Admission for 23 hours observation to the inpatient medical oncology service will be considered if at the end of a study visit either excessive sedation is n oted or RASS score between -3 and -5 or if any severe 
psychological manifestations exist.  
Gastrointestinal system effects: Include nausea, vomiting and increased salivation (due to increased 
salivary and tracheobronchial mucous gland secretions).  Nausea and/or vomiting will be treated with 
IRB00086610                                                                                                                                                                                                   Page 17 of 41 
 
v. 11_ 02.01.19  
  ondansetron 4 to 8 mg IV or PO depending upon severity. Diphenhydramine 6.25 to 25mg IV may be 
given, if no relief from ondansetron or if ondansetron is contraindicated. For increased salivation, not well tolerated by t he patient, glycopyrollate 0.2mg IV may be given if deemed necessary by the study MD. 
Admit if unable to tolerate oral liquid at the end of visit.  
Respiratory effects: Respiratory depression is rare (ventilator response to CO2 is maintained).  Upper 
airway skeletal muscle tone is maintained; upper airway reflexes remain relatively intact.  Respiratory 
depression can occur when ketamine is given in conjunction with other agents (e.g. opioids) or when given 
in large doses or rapid infusions. Treatment may include: decrease/stop opioids and other sedating medications. If respiratory depression (RR < 10/min, O2 sat < 90%) persists at the end of the study visit, the study MD will be notified and potential admission will be considered, the patient‚Äôs will be admit ted 
for 23 hour observation with the inpatient oncology service.  
Ocular effects: Nystagmus (especially vertical nystagmus), diplopia, blurred vision and slight elevation 
in intraocular pressure are possible. If this happens at the end of the study visit, the study MD will 
evaluate for safeness for discharge vs 23 hrs observation.   
Musculoskeletal effects: There is a possibility of increased skeletal tone or tonic- clonic movements. The 
study MD notified if this happens. This will be monitored and treated appropriately. Short acting 
benzodiazepines like IV midazolam may be considered.  
Allergic reaction: Ketamine does not evoke histamine release; and, rarely, if ever causes allergic reaction. If 
an allergic reaction is suspected then the reaction will be treated based on the severity, with steroids and 
antihistamine allergic agents.    
  
 
C.6 Benefits :  
The patient may benefit from improved pain control and improved mood or depression control by 
participating in this research study.  
 
C.7 Participant selection :  
A sample size of 7 from a population of 20 (in the study done by Carr et al.) achieves 91% power to detect 
a NPRS difference of -2.7 between the null hypothesis mean of 0.0 and the alternative hypothesis mean of 
2.7 with an estimated standard deviation of 1.9 and with a significance level (alpha) of 0.05000 using a two-sided Wilcoxon tes t assuming that the actual distribution is normal.  
We need a sample size of 7 patients based on statistical analysis observed in the study done by Carr. We will 
include 10 patients to account for the possibility that the observed pain reduction in the cur rent study may 
be different than the study done by Carr, as in this study patients were given ketamine for breakthrough pain, 
IRB00086610                                                                                                                                                                                                   Page 18 of 41 
 
v. 11_ 02.01.19  
  as opposed to for baseline pain. We will enroll up to 25 patients in the study to account for potential dropouts. 
If a higher dropout rate is observed, then we will enroll more patients until we have at least 10 patients who 
complete the entire study.  
Subject Replacement  
Any subject who does not complete the IV dosing and at least one intranasal dose will be replaced and 
followed for safety as needed and/or via telephone call at 14 days. 
Enrolled subjects who discontinue early will be replaced.  If a subject misses more than one treatment visit during the study period, the subject will be withdrawn and 
replaced to achieve a minimum of 10 subjects who are maximally treated with study medication (4 study 
visits). 
The patients should meet the following inclusion and exclusion criteri a.  
 
C.8 Inclusion Criteri a:  Patients will be eligible to participate if they are:  
 
1. Male and female subjects at least 18 years of age  
2. Patients with uncontrolled pain related to cancer or cancer treatment. Uncontrolled pain will be defined as 
46,47  
i. pain which persists for more than 7 days and is rated >/=4 on NPRS  
ii. use of breakthrough medication more than 4 times in 24 hours or being 
treated with oral morphine equivalent of 50 mg/d or more   
 
3. Patients who are48 able to follow -up in person during the trial  
4. Patient on stable analgesic regimen for >7 days without escalation during study period 
with rescue or immediate release medication every 3 hours or longer  
5. Patients who are willing and able to maintain a daily pain diary   
6. Patients who are able to understand written and verbal English  
7. Patient weight >/= 50 kg  
  
C.9 Exclusion Criteri a: Patients will be excluded from the study if they have any of the 
following:  
 
1. Transportation issues interfering with return study visits   
2. Patients with high disposition of laryngospasm or apnea  
3. Presence of severe cardiac disease  
IRB00086610                                                                                                                                                                                                   Page 19 of 41 
 
v. 11_ 02.01.19  
  4. Presence of conditions where significant elevations in blood pressure would be a serious 
hazard.  
5. Stage 2 hypertension or greater (systolic blood pressure > 160 and/or d iastolic blood 
pressure >100)  
6.  Baseline tachycardia, HR >100  
7. History of seizures, elevated ICP or CSF obstructive states(e.g. severe head injury, 
central congenital or mass lesions)  
8. Conditions that may increase intraocular pressure (e.g. glaucoma, acute globe injury)  
9. History of uncontrolled depression or other psychiatric comorbidity with psychosis  
10. History of liver disease  
11. History of interstitial cystitis  
12. History of nasal or sinus anomalies or dysfunction e.g. allergic or infectious rhinitis.  
13. Patients with lesions to the nasal mucosa  
14. Pregnant women, nursing mothers and women of childbearing potential not using 
contraception known to be highly effective. Highly effective contraception  methods 
include combination of any two of the following:  
i. Use of oral, injected or implanted hormonal methods of contraception 
or;  
ii. Placement of an intrauterine device (IUD) or intrauterine system (IUS);   
iii. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;  
iv. Total abstinence;  
v. Male/female sterilization.  
15. Illicit substance abuse within the past 6 months  
16. Documented history of medication abuse/misuse (e.g.  Unsanctioned dose escalation, broken opioid agreement etc.) 
17. Clinical requirement for medications that are  concurrent indu cers or strong inhibitors of 
CYP3A4. CYP3A4 substrates are allowed. ( Appendix II-D) 
18. Porphyria (possibility of triggering a porphyric reaction)  
19. Severe active anemia ( a hemoglobin< 8 documented by labs drawn within 3 months of 
first study treatment )  
20. History of difficult intravenous access  
21. Intractable vomiting  
IRB00086610                                                                                                                                                                                                   Page 20 of 41 
 
v. 11_ 02.01.19  
    
 C.10 Informed Consent Process:  
Informed consent will be obtained by a research team member delegated to do so by the PI, prior to 
conducting any research procedures. This process will include a discussion of risks and benefits, as well 
as answering patient questions. If patients are able to provide their own medical history, they will be deemed capable of providing informed consent for research participation. The process will be free of coercion. Study patients will be paid a small amount to reimburse for travel expenses for each visit 
completed. They can withdraw at any time without penalty to their ongoing care.  
  
C.11 Compensation for time and effort :  
A compensation of $50 per visit will occur with each patient for each completed visit to reimburse for 
travel expenses to and from the institution.  
  
C.12 Statistical analysis :   
 
Study results will be analyzed as below to achieve the study objectives:  
 
1. Determine pharmacokinetics of intranasal ketamine.  
Concentrations of ketamine and its metabolite norketamine will be analyzed to determine pharmacokinetic characteristics such as bioavailability, peak effect and elimination.  
2. Determine pharmacodynamics of intranasal ketamine in terms of Patient Reported 
Outcomes  
i. Pain scores on NPRS will be analyzed by Wilcoxon signed -rank test as 
the study sample size is too small to be analyzed by paired ‚Äìt test. 
Generalized Linear Model will  be used to model any time trend for pain 
score change and to test if the trend is significant.  
ii. T-test will be used to compare any changes in depression severity on 
MADRS.  
iii. Chi-square test will be used to test presence/absence of any side effects. 
Wilcoxon signed rank test will be used to assess the severity of all the 
side effects (including SERSDA) , if needed.   
iv. Paired T-test will be used to asses any changes in functional status on 
PROMIS scale.   
v. T-test will be used to compare any changes in ESAS and E COG.  
3. Determine PK-PD relationships of NAS ketamine delivered  
IRB00086610                                                                                                                                                                                                   Page 21 of 41 
 
v. 11_ 02.01.19  
  Timing, degree and dur ation of change in pain scores will be compared 
with individual and group pharmacokinetic parameters to assess 
potential relationships between measures of exposure ( Cmax, and AUC 0-
t) and pain relief. Multivariate modeling including patient -specific data 
(age, sex, weight, BMI, morphine equivalents) will be performed using 
initial PK parameters and goodness of fit analyses for compartmental model selection. If applicable, da ta from vital sign measurement 
changes will also be used as comparison with pharmacokinetic data. 
4. Determine opioid sparing effect of intranasal ketamine.   
i. Chi-square test will be used to compare frequency of rescue medication 
use.  
ii. T-test will be used to compare total opioid consumption.  
 
 
C.13 Data and Safety Monitoring and Reporting  Plan:   
 
1. This study will be followed by the Winship Cancer Institute Data Safety Monitoring Committee 
(DSMC) for local review and confirmation  of proper study execution and safety measures. Initial study 
monitoring will occur within 6 months from the date of the first subject accrued, with 2 of the first 5 subjects reviewed. Therefore, subsequent monitoring will occur in six month intervals if any subjects were accrued. The population continuing to receive intervention will be monitored as determined by the DSMC. At minimum, 10% of subjects accrued since previous monitoring will be reviewed. An 
additional subject (or subjects) may be selected based on previously noted monitoring deficiencies or at DSMC discretion.  Continued monitoring will occur in six month intervals for the population continuing to receive intervention as determined by the DSMC. 
 
The DSMC will review pertinent aspects of the study conduct including patient safety, protocol 
compliance, data collection, and efficacy. The PI or designee will be responsible for notifying the DSMC of patient accrual and status updates within two months of the planned review. 
 
2. Procedures to assure data integrity and protocol adherence:  
a) A monthly meeting of investigators, clinical research coordinators and regulatory personnel 
will be held to review the clinical data.  
b) Adverse event reporting will utilize the Common Terminology C riteria for Adverse Events  
CTCAE) version 5 .0. The grading scale for these adverse events is as follows:    
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic  observations only; 
intervention not indicated.  
IRB00086610                                                                                                                                                                                                   Page 22 of 41 
 
v. 11_ 02.01.19  
  Grade 2 Moderate; minimal, local or noninvasive intervention indicated;  limiting age 
appropriate instrument al activities of daily living ( ADL) 
Grade 3 Severe or medically significant but  not immediately  life-threatening; hospitalization  
or prolongation of hospitalization indicated; disabling; limiting self -care ADL 
Grade 4 Life- threatening consequences; urgent intervention indicated  
Grade 5 Death related to AE. 
c) A serious adverse event (SAE) is an AE or suspected adverse drug reaction that fulfills one 
of the following:  
‚Ä¢ results in death  
‚Ä¢ is immediately life -threatening (life -threatening in the definition of SAE refers to an  
event in which the subject was at immediate risk of death at the time of the event; it does  
not refer to an event which hypothetically might have caused de ath if it were more  
severe). 
‚Ä¢ requires in -subject hospitalization or prolongation of existing hospitalization  
‚Ä¢ results in persistent or significant disability or incapacity  
‚Ä¢ is a congenital anomaly or birth defect 
‚Ä¢ is an important medical event: important medical event in the definition of ‚Äúserious  
refers to those events which may not be immediately life-threatening, or result in 
death, or hospitalization, but from medical and scientific judgment may jeopardize the 
subject and/or may require medical or surgical intervention to prevent one of the other 
outcome listed above. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization. Development of cancer or drug 
dependency or drug abuse will normally be considered serious by this criterion.  
d) Study progress in terms of enrollment and activity of current patients will be reviewed during 
the monthly meeting of the investigators, clinical research coordinators and regulatory 
personnel. The PI may increase the frequency of this meeting if necessary.  
e) Study specific training of all study personnel, including management of potential adverse 
events, will occur prior to initiating study enrollme nt using the final a pproved protocol and 
study specific standard operating procedure document. Training of the Phase I staff will be 
conducted by the team clinical research coordinator prior to study enrollment. Completion 
of training will be documented on a study training log and stored in the regulatory binder.  
Investigators will complete CITI training as well as any additional training required by the 
Emory Office for Clinical Research.  
IRB00086610                                                                                                                                                                                                   Page 23 of 41 
 
v. 11_ 02.01.19  
   
3. Clinical monitoring will occur as previously described (Study Methods).  
 
4. As the  IND sponsor- investigator,  unexpected fatal or life threatening suspected adverse reactions 
will be reported using the Medwatch FDA form 3500A via FedEx to the FDA no later than 7 calendar 
days after the initial receipt of information (21CFR 312.32(C)(2)) .  Additionally, serious, unexpected 
suspected adverse reactions and a clinically important increase in the rate of a serious suspected 
adverse reaction will be reported to no later than 15 c alendar days after determining th e information 
qualifies for reporting (21 CFR 312.32 (C) (1)) in paper format  using FDA form 3500A. Finally, an 
annual progress report will be provided within 60 days of the anniversary date that the IND became active , January 20, 2017, (21 CFR 312.33). 
 
5. Patient data will be evaluated by the PI on an ongoing basis during the study visits to observe for any 
trends in adverse effects of the study treatment, to ensure continued subject safety and to ensure the 
scientific validity of the trial. Adverse events (AE) will be recorded. An adverse event i s defined as 
any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product or  study treatment and that does not necessarily have a causal relationship 
with this administration .  An AE can therefore be any unfavorable and unintended sign (including 
any abnormal laboratory findings ), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Adverse ev ents will be captured from the time of the first study drug administration through the fifth 
study visit. Ongoing a dverse events at the fifth visit will be follow ed with a telephone call visit 14 
days (plus or minus 1 day) after the last medication adminis tration. AEs will be reported to the PI by 
Emory email or telephone . All adverse events will  be documented in an AE log. The reporting 
policy of the Emory IRB will be followed.  
  
6. The study will be stopped after a hospitalization that is related  to study drug administration f or a formal 
review by the PI and the DSMC . When a hospitalization related to study drug administration occurs, 
the study will be put on hold. The PI or delegated person will communicate the event details to the 
DSMC for their  review and determination of approval to continue the study. The study will be ended 
if there is more than one hospitalization related to the study drug administration.  
 
7. The Emory University School of Medicine Department of Anesthesiology will conduct this study according to national rules, regulations and guidelines governing human clinical research. In addition, 
IRB00086610                                                                                                                                                                                                   Page 24 of 41 
 
v. 11_ 02.01.19  
  procedures cited by the US Code of Federal Regulations (Title 21) will be followed as these apply to 
the principles of Good Clinical Practice and approval by the Emory University Institutional Review Board (IRB).   
 
 
Confidentiality : The privacy of the research subjects will be ensured through the standard procedures for 
securing research data. All records identifying the subject will be kept confidential and, to the extent 
permitted by the applicable laws and regulations, will not be made publicly available.  Subjects will be 
identified by a study number. If the results of the study are published, the subject‚Äôs identity will remain confidential.  
  
C.14 Potential Pitfalls:  
 
Lack of blinding/Lack of placebo arm . There is enough evidence to support an analgesic effect of 
ketamine. Since the study is being conducted in cancer pain patients and involves blood draws and 
transport, a placebo arm is considered to be unethical in these circu mstances.  The possibility exists that  
ketamine might have long term effects beyond its duration of action and the pain scores might be 
significantly lower than the compared to at the beginning of the study. In this case change in pain score 
may not be sign ificant during the later study visits . However, overall this would be a good effect for 
pain control and can future studies can be designed to account for this effect. As cancer pain can be 
evolving and changing, the decision was made to finish all the study visits in the least possible duration of time, as possible.  Once feasibility and safety is established with this study, the aim of future studies will 
be allow patients to take this medication at home for maintenance. Lack of standard opioid regimen 
among patients could be problematic in terms of comparison of outcomes.  
 
 
E. REFERENCES/BIBLIOGRAPHY  
  
1. van den Beuken- van Everdingen, M. H. et al. Prevalence of pain in patients with cancer: 
a systematic review of the past 40 years. Ann Oncol  18, 1437-1449, 
doi:10.1093/annonc/mdm056 (2007).  
 
2. Malinovsky. Ketamine and norketamine plasma concentrations after i.v., nasal and 
rectal administration in children. Br J Anaesth.  , 77(72):203-207 (1996 Aug;).  
 
3. Reich, D. L. & Silvay, G. Ketamine: an updat e on the first twenty -five years of clinical 
experience. Can J Anaesth 36, 186-197, doi:10.1007/BF03011442 (1989).  
 
IRB00086610                                                                                                                                                                                                   Page 25 of 41 
 
v. 11_ 02.01.19  
  4. White, P. F., Way, W. L. & Trevor, A. J. Ketamine --its pharmacology and therapeutic 
uses. Anesthesiology  56, 119-136 (1982).  
 
5. Yakovlev, A. E. & Ellias, Y. Spinal cord stimulation as a treatment option for intractable 
neuropathic cancer pain. Clin Med Res  6, 103-106, doi:10.3121/cmr.2008.813 (2008).  
 
6. Sloan, P. & Melzack, R. Long- term patterns of morphine dosage and pain intensity 
among cancer patients. Hosp J 14, 35- 47 (1999).  
 
7. Peng, L., Min, S., Zejun, Z., Wei, K. & Bennett, M. I. Spinal cord stimulation for cancer-
related pain in adults. Cochrane Database Syst Rev 6, CD009389, 
doi:10.1002/14651858.CD009389.pub3 (2015).  
8. Horton, R. & Barber, C. Opioid- induced respiratory depression resulting from 
transdermal fentanyl -clarithromycin drug interaction in a p atient with advanced COPD. 
J Pain Symptom Manage  37, e2-5, doi:10.1016/j.jpainsymman.2009.02.230 (2009).  
 
9. Brennan, M. J. The clinical implications of cytochrome p450 interactions with opioids and strategies for pain management. J Pain Symptom Manage  44, S15-22, 
doi:10.1016/j.jpainsymman.2012.08.012 (2012).  
 
10. Hersh, E. V., Pinto, A. & Moore, P. A. Adverse drug interactions involving common prescription and over -the-counter analgesic agents. Clin Ther  29 Suppl , 2477-2497, 
doi:10.1016/j.clinthera.2007.12.003 (2007).  
 
11. Golembiewski, J. Opioid- induced pruritus. J Perianesth Nurs  28, 247-249, 
doi:10.1016/j.jopan.2013.05.008 (2013).  
 
12. Warner, E. A. Opioids for the treatment of chronic noncancer pain. Am J Med  125, 1155 -
1161, doi:10.1016/j.amjmed.2012.04.032 (2012).  
 
13. Lee, M., Silverman, S. M., Hansen, H., Patel, V. B. & Manchikanti, L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 14, 145-161 (2011).  
 
14. Brack, A., Rittner, H. L. & Stein, C. Immunosuppressive effects of opioids --clinical 
relevance. J Neuroimmune Pharmacol  6, 490-502, doi:10.1007/s11481-011-9290-7 
(2011).  
 
15. Katz, N. & Mazer, N. A. The impact of opioids on the endocrine system. Clin J Pain  
25, 170-175, doi:10.1097/AJP.0b013e3181850df6 (2009).  
 
16. Vuong, C., Van Uum, S. H., O'Dell, L. E., Lutfy, K. & Friedman, T. C. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev  31, 
98-132, doi:10.1210/er.2009-0009 (2010).  
 
17. Spadotto, V., Zorzi, A., Elmaghawry, M., Meggiolaro, M. & Pittoni, G. M. Heart failure due to 'stress cardiomyopathy': a severe manifestation of the opioid withdrawal 
syndrome. Eur Heart J Acute Cardiovasc Care 2, 84-87, doi:10.1177/2048872612474923 (2013).  
IRB00086610                                                                                                                                                                                                   Page 26 of 41 
 
v. 11_ 02.01.19  
   
18. Larcher, A., Laulin, J. P., Celerier, E., Le Moal, M. & Simonnet, G. Acute toleran ce 
associated with a single opiate administration: involvement of N -methyl-D-aspartate-
dependent pain facilitatory systems. Neuroscience 84, 583-589 (1998).  
 
19. Dale, O., Hjortkjaer, R. & Kharasch, E. D. Nasal administration of opioids for pain 
management in adults. Acta Anaesthesiol Scand 46, 759 -770 (2002).  
 
20. Carr, D. B.  et al. Safety and efficacy of intranasal ketamine for the treatment of 
breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain  108, 17-27,doi:10.1016/j.pain.2003.07.001 (2004).  
 
21. Lapidus, K. A. et al.  A randomized controlled trial of intranasal ketamine in major 
depressive disorder. B iol Psychiatry  76, 970-976, doi:10.1016/j.biopsych.2014.03.026 
(2014).  
 
22. Bell, R. F., Eccleston, C. & Kalso, E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage 26, 867-875 (2003).  
 
23. Yanagihara, Y.  et al. Plasma concentration profiles of ketamine and norketamine after 
administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos  24, 37-43, doi:10.1002/bdd.336 (2003).  
 
24. Clements, J. A. & Nimmo, W. S. Pharmacokinetics and analgesic effect of ketamine in 
man. Br J Anaesth  53, 27-30 (1981).  
 
25. Grant, I. S., Nimmo, W. S. & Clements, J. A. Pharmacokinetics and analgesic effects 
of i.m. and oral ketamine. Br J Anaesth  53, 805-810 (1981).  
 
26. Malinovsky, J. M., Servin, F., Cozian, A., Lepage, J. Y. & Pinaud, M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth  77, 203-207 (1996).  
 
27. Clements, J. A., Nimmo, W. S. & Grant, I. S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci  71, 539-542 (1982).  
 
28. Christensen, K. Safety and efficacy of intranasal ketamine for acute postoperative pain.  9, 183‚Äì 192 (2007).  
 
29. Ferreira-Valente, M. A., Pais-Ribeiro, J. L. & Jensen, M. P. Validity of four pain intensity rating scales. Pain 152, 2399-2404, doi:10.1016/j.pain.2011.07.005 (2011).  
 
30. Hjermstad, M. J.  et al. Studies comparing Numerical Rating Scales, Verbal Rating 
Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage  41, 1073-1093, 
doi:10.1016/j.jpainsymman.2010.08.016 (2011). 
 
31. Bombardier, C., Hayden, J. & Beaton, D. E. Minimal clinically important difference. Low back pain: outcome measures. J Rheumatol  28, 431-438 (2001).  
IRB00086610                                                                                                                                                                                                   Page 27 of 41 
 
v. 11_ 02.01.19  
   
32. Lee, J. S., Hobden, E., Stiell, I. G. & Wells, G. A. Clinically important change in the 
visual analog scale after adequate pain control. Acad Emerg Med  10, 1128-1130 
(2003).  
 
33. van der Roer, N., Ostelo, R. W., Bekkering, G. E., van Tulder, M. W. & de Vet, H. C. Minimal clinically important change for pain intensity,  functional status, and general 
health status in patients with nonspecific low back pain. Spine (Phila Pa 1976)  31, 
578-582, doi:10.1097/01.brs.0000201293.57439.47 (2006).  
 
34. Kovacs, F. M. et al.  Minimal clinically important change for pain intensity and 
disability in patients with nonspecific low back pain. Spine (Phila Pa 1976)  32, 2915-
2920, doi:10.1097/BRS.0b013e31815b75ae (2007).  
 
35. Kovacs, F. M. et al.  Minimum detectable and minimal clinically important changes for 
pain in patients with nonspecific neck pain. BMC Musculoskelet Disord  9, 43, 
doi:10.1186/1471-2474-943 (2008).  
 
36. Farrar, J. T., Young, J. P., Jr., LaMoreaux, L., Werth, J. L. & Poole, R. M. Clinical importance of changes in chronic pain intensity measured on an 11- point numerical 
pain rating scale. Pain  94, 149-158 (2001).  
 
37. Montgomery, S. A. & Asberg, M. A new depre ssion scale designed to be sensitive to 
change. Br J Psychiatry 134, 382-389 (1979).  
 
38. Hardy, J. et al. Randomized, double-blind, placebo- controlled study to assess the 
efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 30, 36113617, doi:10.1200/JCO.2012.42.1081 (2012).  
 
39. Blonk, M. I., Koder, B. G., van den Bemt, P. M. & Huygen, F. J. Use of oral ketamine in chronic pain management: a review. Eur J Pain  14, 466-472, 
doi:10.1016/j.ejpain.2009.09.005 (2010).  
 
40. Lauretti, G. R., Gomes, J. M., Reis, M. P. & Pereira, N. L. Low doses of epidural 
ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J Clin Anesth 11, 663-668 (1999).  
 
41. Mercadante, S., Arcuri, E., Ferrera, P., Villari, P. & Mangione, S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage  30, 485-491, doi:10.1016/j.jpainsymman.2005.04.014 
(2005). 
 
42. Visser, E. & Schug, S. A. The role of ketamine in pain management. Biomed Pharmacother  60, 341-348, doi:10.1016/j.biopha.2006.06.021 (2006).  
 
43. Bell, R. F. Ketamine for chronic non-cancer pain. Pain 141, 210-214, doi:10.1016/j.pain.2008.12.003 (2009).  
 
IRB00086610                                                                                                                                                                                                   Page 28 of 41 
 
v. 11_ 02.01.19  
  44. Okon, T. Ketamine: an introduction for the pain and palliative medicine physician. 
Pain Physician  10, 493-500 (2007).  
 
45. Bredlau, A. L., Thakur, R., Korones, D. N. & Dworkin, R. H. Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med 14 , 15051517, doi:10.1111/pme.12182 (2013).  
 
46. Kim, H. J., Kim, Y. S. & Park, S. H. Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study. BMC Palliat Care  14, 
41, doi:10.1186/s12904015-0038-7 (2015).  
 
47. Woo, A. et al. Cut points for mild, moderate, and severe pain among cancer and non-
cancer patients: a literature review. Ann Palliat Med  4, 176-183, 
doi:10.3978/j.issn.22245820.2015.09.04 (2015).  
 
48. Bohnert, A. S. et al.  Association between opioid prescribing patterns and opioid 
overdoserelated deaths. JAMA 305, 1315- 1321, doi:10.1001/jama.2011.370 (2011).  
 
49. Eide, P. K., Jorum, E., Stubhaug, A., Bremnes, J. & Breivik, H. Relief of post- herpetic 
neuralgia with the N- methyl-D- aspartic acid receptor antagonist keta mine: a double-
blind, cross-over comparison with morphine and placebo. Pain  58, 347-354 (1994).  
50. Hijazi, Y. & Boulieu, R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-
demethylation of ketamine in human liver microsomes. Drug Metab Dispos  30, 853-858 (2002). 
 
 
     
 
       
 
IRB00086610                                                                                                                                                                                                   Page 29 of 41 
 
v. 11_ 02.01.19  
   
  
Appendix I: Assessment scales used in the study (click on files  G, H, and I  to open the files). 
 
A. Numerical pain rating scale.  
 
B. SERSDA ‚ÄìSide Effects Rating Scale for Dissociative Anesthetics [20, 40] 
Side effects  Severity of side effects scale  
Fatigue 0, no change  
Dizziness  1, weak  
Nausea 2, modest  
Headache  3, bothersome   
Feeling of unreality  4, very bothersome  
Changes in hearing   
Changes in vision   
Mood change  
Generalized discomfort   
Hallucination   
 
 
C. ECOG score  
GRADE ECOG PERFORMANCE STATUS  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self -care but unable to carry out any work activities; up and 
about more than 50% of waking hours  
3 Capable of only limited self- care; confined to bed or chair more than 50% of waking hours  
4 Completely disabled; cannot carry on any self -care; totally confined to bed or chair  

IRB00086610                                                                                                                                                                                                   Page 30 of 41 
 
v. 11_ 02.01.19  
  5 Dead 
 
 
  
D. ESAS score  - Edmonton Symptom Assessment System   
Please circle the number that best describes how you feel NOW:  
No Pain                  0 1 2 3 4 5 6 7 8 9 10 Worst Possible Pain  
  
No Tiredness            0 1 2 3 4 5 6 7 8 9 10 Worst Possible Tiredness  
(Tiredness = lack of energy)  
  
No Drowsiness          0 1 2 3 4 5 6 7 8 9 10 Worst Possible Drowsiness  
(Drowsiness = feeling sleepy)  
  
No Nausea              0 1 2 3 4 5 6 7 8 9 10 Worst Possible Nausea  
  
No Lack of Appetite 0 1 2 3 4 5 6 7 8 9 10 Worst Possible Lack of Appetite  
  
No Shortness of Breath 0 1 2 3 4 5 6 7 8 9 10 Worst Possible Shortness of Breath  
  
No Depression            0 1 2 3 4 5 6 7 8 9 10 Worst Possible Depression  
(Depression = feeling sad)  
  
No Anxiet y                0 1 2 3 4 5 6 7 8 9 10 Worst Possible Anxiety  
(Anxiety = feeling nervous)  
  
Best Wellbeing     0 1 2 3 4 5 6 7 8 9 10 Worst Possible  Wellbeing   
(Wellbeing = how you feel overall)  
  
No __________       0 1 2 3 4 5 6 7 8 9 10 Worst possible __________   
Other Problem (for example constipation)  
 
  
 
  
IRB00086610                                                                                                                                                                                                   Page 31 of 41 
 
v. 11_ 02.01.19  
   
 
 
  
E. RASS Scale to Assess Sedation. -PDF file.    
 
   
  
       
IRB00086610                                                                                                                                                                                                   Page 32 of 41 
 
v. 11_ 02.01.19  
   
  
F. CAM scale to assess for delirium if RASS score is between +4  to -3. ‚ÄìPDF file.    
 
 
 
  
    
   
 
 
 
  
 
 
IRB00086610                                                                                                                                                                                                   Page 33 of 41 
 
v. 11_ 02.01.19  
   
  
G. PHQ-9 questionnaire. -PDF file.   
IRB00086610                                                                                                                                                                                                   Page 34 of 41 
 
v. 11_ 02.01.19  
  
 
 
   
IRB00086610                                                                                                                                                                                                   Page 35 of 41 
 
v. 11_ 02.01.19  
  H. MADRS questionnaire to be filled out based on clinical interview during the study. -PDF file  
 
I. PROMIS  questionnaire .  
IRB00086610                                                                                                                                                                                                   Page 36 of 41 
 
v. 11_ 02.01.19  
  
 
 
J. Weekly Pain Diary  
IRB00086610                                                                                                                                                                                                   Page 37 of 41 
v. 11_ 02.01.19 
  
 
Appendix II: Ketamine related information (click on files A, B,  and C to open the files) 
$Test summary sheets from  NMS labs where ketamine and its me tabolites will be measured.  

Lab testing ketamine.xps 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
  
IRB00086610                                                                                                                                                                                                   Page 38 of 41 
 
v. 11_ 02.01.19  
   
B.   Ketamine product insert . ‚ÄìPDF file 
 
IRB00086610                                                                                                                                                                                                   Page 39 of 41 
 
v. 11_ 02.01.19  
   
C.   Ketamine 500mg/5ml multidose vial safety data sheet from manufacturer, Hospira. -PDF   file.  
 
IRB00086610                                                                                                                                                                                                   Page 40 of 41 
 
v. 11_ 02.01.19  
  D. -Cytochrome P450 3A4 and 3A5 Known Drug Interaction Chart  
CYP3A4 and CYP3A5 Substrates  CYP3A4 and CYP3A5 Inhibitors  
ANTIHISTAMINES  NEUROPSYCHIATRIC  STRONG INHIBITORS  
astemizole  alprazolam  clarithromycin  
chlorpheniramine  diazepam   indinavir  
ANTIMETRIC  midazolam  itraconazole  
aprepitant  triazolam  ketoconazole  
ondansetron  haloperidol  nefazodone  
ANESTHESIA/PAIN  aripiprazole  ritonavir  
cafergot  buspirone  saquinavir  
codeine -N-demethylation  carbamazepine  suboxone  
fentanyl  pimozide  telithromycin  
levolevomethadyl acetate (LAAM)  quetiapine  INTERMEDIATE STRENGTH INHIBITORS  
lidocaine,   risperidone  aprepitant  
methadone  trazodone  erythromycin  
ANTIBIOTIC/ANTIVIRAL  zaleplon  fluconazole  
alfentanil  ziprasidone  grapefruit juice  
boceprevir  zolpidem  verapamil  
clarithromycin  ONCOLOGY  diltiazem  
efavirenz  docetaxel  WEAK INHIBITORS  
erythromycin (not CYP3A5),  gleevec  cimetidine  
indinavir  irinotecan  OTHER POSSIBLE INHIBITORS  
nelfinavir  paclitaxel  amiodarone  
nevirapine  romidepsin  boceprevir  
quinine  sorafenib  chloramphenicol  
ritonavir  sunitinib  ciprofloxacin  
saquinavir  torisel  delaviridine  
telaprevir  vemurafenib  diethyl -dithiocarbamate  
telithromycin.  vincristine  fluvoxamine  
CARDIOVASCULAR  PULMONARY  gestodene  
amlodipine  salmeterol  imatinib  
cilostazol  sildenafil  mibefradil  
diltiazem  STEROID  mifepristone  
eplerenone  dexamethasone  norfloxacin  
lercanidipine  estradiol  norfluoxetine  
nifedipine  hydrocortisone  starfruit  
nisoldipine  progesterone  telaprevir  
nitrendipine  testosterone  voriconazole  
propranolol  OTHER   
quinidine (not CYP3A5)  cocaine   
verapamil  dapsone   
HMG COA REDUCTASE INHIBITORS  dextromethorphan   
atorvastatin  finasteride   
lovastatin  
simvastatin  
IMMUNE MODULATORS  
cyclosporine 
sirolimus 
tacrolimus  nateglinide   
IRB00086610                                                                                                                                                                                                   Page 41 of 41 
 
v. 11_ 02.01.19  
   
CYP3A4 and CYP3A5 Inducers  
barbiturates 
carbamazepine 
efavirenz 
glucocorticoids 
modafinil nevirapine oxcarbazepine phenobarbital phenytoin 
pioglitazone 
rifabutin rifabutin
 
St. John's Wort troglitazone
 
 
 